María Victoria
Mateos Manteca
Profesora Titular de Universidad
Hospital Universitario Central de Asturias
Oviedo, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (19)
2024
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
2023
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852
2021
-
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Leukemia, Vol. 35, Núm. 1, pp. 245-249
-
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420
2020
-
Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT
Bone Marrow Transplantation
2019
-
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Blood, Vol. 134, Núm. 16, pp. 1337-1345
2015
-
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial
Haematologica, Vol. 100, Núm. 8, pp. 1096-1102
-
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial
Haematologica, Vol. 100, Núm. 9, pp. 1207-1213
2014
-
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma
Blood, Vol. 124, Núm. 8, pp. 1300-1303
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
-
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Haematologica, Vol. 95, Núm. 11, pp. 1913-1920
2009
2008
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
Haematologica, Vol. 93, Núm. 4, pp. 560-565
-
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Blood, Vol. 112, Núm. 10, pp. 4017-4023
2007
-
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
Leukemia, Vol. 21, Núm. 1, pp. 143-150
2003
-
Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome
Annals of Oncology, Vol. 14, Núm. 5, pp. 745-751
2000
-
Two new 3' PML breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia
Genes Chromosomes and Cancer, Vol. 27, Núm. 1, pp. 35-43